Core Viewpoint - Zhifei Biological announced the acquisition of an invention patent for a vaccine that can prevent Helicobacter pylori infection, along with its preparation method [1] Company Summary - Zhifei Biological and its wholly-owned subsidiaries, Beijing Zhifei Lvzhu Biological Pharmaceutical Co., Ltd. and Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd., received the invention patent certificate from the National Intellectual Property Administration of the People's Republic of China [1]

Group 1 - The core point of the news is that Zhifei Biological has obtained a patent for a vaccine that can prevent Helicobacter pylori infection, which may enhance its product portfolio and market position [1] - Zhifei Biological's revenue composition for the year 2024 is projected to be 99.14% from biological products and 0.86% from other businesses, indicating a strong focus on its core offerings [1] - As of the latest report, Zhifei Biological has a market capitalization of 50.2 billion yuan, reflecting its significant presence in the biotechnology sector [2]